There is no consensus on the dose of rituximab to be used, the interval between infusions, and need for repeat infusions.The use of rituximab is an evolving work in progress.Available data has limitations but the drug is effective.Whether this control is long term, or of limited duration is not known.A protocol that is unique for autoimmune mucocutaneous blistering disease is needed. Rituximab in low dose is the new frontier for the treatment of pemphigus....
To read the complete article
create a free
to instantly read 30000+ free Articles & 1000+ Case Studies